At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Tirzepatide for Psoriasis and Obesity. Completed, enrolled 281 participants across 72 sites in 2 countries.
Signals
Detailed Summary
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
Study Details
Timeline
Arms & Interventions
Ixekizumab administered subcutaneous (SC).
Ixekizumab concomitantly administered with tirzepatide SC.
Interventions
Administered SC
Administered SC.